Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021

 

Upgrades

  • For Toll Brothers Inc TOL, BTIG upgraded the previous rating of Sell to Neutral. In the second quarter, Toll Brothers showed an EPS of $1.01, compared to $0.59 from the year-ago quarter. At the moment, the stock has a 52-week-high of $68.88 and a 52-week-low of $28.91. Toll Brothers closed at $57.73 at the end of the last trading period.
  • Citigroup upgraded the previous rating for Unity Biotechnology Inc UBX from Sell to Buy. For the first quarter, Unity Biotechnology had an EPS of $0.29, compared to year-ago quarter EPS of $0.59. At the moment, the stock has a 52-week-high of $15.44 and a 52-week-low of $2.72. Unity Biotechnology closed at $4.34 at the end of the last trading period.
  • For Brookfield Renewable Partners LP BEP, Credit Suisse upgraded the previous rating of Neutral to Outperform. For the first quarter, Brookfield Renewable had an EPS of $0.24, compared to year-ago quarter EPS of $0.06. The stock has a 52-week-high of $97.41 and a 52-week-low of $34.55. At the end of the last trading period, Brookfield Renewable closed at $37.38.
  • For Macerich Co MAC, Deutsche Bank upgraded the previous rating of Hold to Buy. In the first quarter, Macerich showed an EPS of $0.45, compared to $0.81 from the year-ago quarter. The stock has a 52-week-high of $25.99 and a 52-week-low of $6.42. At the end of the last trading period, Macerich closed at $18.43.
  • According to Stephens & Co., the prior rating for International Paper Co IP was changed from Equal-Weight to Overweight. International Paper earned $0.76 in the first quarter, compared to $0.57 in the year-ago quarter. The current stock performance of International Paper shows a 52-week-high of $65.27 and a 52-week-low of $32.59. Moreover, at the end of the last trading period, the closing price was at $60.68.
  • According to Stifel, the prior rating for Nektar Therapeutics NKTR was changed from Hold to Buy. In the first quarter, Nektar Therapeutics showed an EPS of $0.68, compared to $0.53 from the year-ago quarter. At the moment, the stock has a 52-week-high of $26.75 and a 52-week-low of $15.39. Nektar Therapeutics closed at $17.27 at the end of the last trading period.

See all analyst ratings upgrades.

 

Downgrades

  • RBC Capital downgraded the previous rating for Sandstorm Gold Ltd SAND from Sector Perform to Underperform. In the first quarter, Sandstorm Gold earned $0.03. The current stock performance of Sandstorm Gold shows a 52-week-high of $10.63 and a 52-week-low of $5.96. Moreover, at the end of the last trading period, the closing price was at $8.08.
  • According to Raymond James, the prior rating for Maximus Inc MMS was changed from Strong Buy to Outperform. In the second quarter, Maximus showed an EPS of $1.29, compared to $0.82 from the year-ago quarter. At the moment, the stock has a 52-week-high of $96.05 and a 52-week-low of $64.30. Maximus closed at $92.28 at the end of the last trading period.
  • According to JP Morgan, the prior rating for Global Blood Therapeutics Inc GBT was changed from Overweight to Neutral. For the first quarter, Global Blood Therapeutics had an EPS of $1.21, compared to year-ago quarter EPS of $1.20. The stock has a 52-week-high of $76.27 and a 52-week-low of $34.65. At the end of the last trading period, Global Blood Therapeutics closed at $36.44.
  • For BRF SA BRFS, Goldman Sachs downgraded the previous rating of Buy to Neutral. In the first quarter, BRF showed an EPS of $0.01, compared to $0.01 from the year-ago quarter. The current stock performance of BRF shows a 52-week-high of $6.08 and a 52-week-low of $2.85. Moreover, at the end of the last trading period, the closing price was at $5.73.

See all analyst ratings downgrades.

 

Initiations

  • Citigroup initiated coverage on DLocal Ltd DLO with a Neutral rating. The price target for DLocal is set to $50.00. The current stock performance of DLocal shows a 52-week-high of $49.90 and a 52-week-low of $29.57. Moreover, at the end of the last trading period, the closing price was at $47.79.
  • Aegis Capital initiated coverage on Meten EdtechX Education Group Ltd METX with a Buy rating. The price target for Meten EdtechX Education is set to $3.00. Interestingly, in the first quarter, Meten EdtechX Education's EPS was $0.13. The stock has a 52-week-high of $12.43 and a 52-week-low of $0.90. At the end of the last trading period, Meten EdtechX Education closed at $0.99.
  • With a Buy rating, Maxim Group initiated coverage on Compass Pathways PLC CMPS. The price target seems to have been set at $70.00 for Compass Pathways. Interestingly, in the first quarter, Compass Pathways's EPS was $0.35. At the moment, the stock has a 52-week-high of $61.69 and a 52-week-low of $22.51. Compass Pathways closed at $33.49 at the end of the last trading period.
  • Maxim Group initiated coverage on Enveric Biosciences Inc ENVB with a Buy rating. The price target for Enveric Biosciences is set to $6.00. In the first quarter, Enveric Biosciences showed an EPS of $0.20, compared to $0.02 from the year-ago quarter. At the moment, the stock has a 52-week-high of $7.00 and a 52-week-low of $1.85. Enveric Biosciences closed at $2.17 at the end of the last trading period.
  • Roth Capital initiated coverage on BioAtla Inc BCAB with a Buy rating. The price target for BioAtla is set to $75.00. BioAtla earned $0.56 in the first quarter. The stock has a 52-week-high of $76.63 and a 52-week-low of $27.15. At the end of the last trading period, BioAtla closed at $42.75.
  • With a Neutral rating, Wedbush initiated coverage on Squarespace Inc SQSP. The price target seems to have been set at $70.00 for Squarespace. The stock has a 52-week-high of $64.71 and a 52-week-low of $42.82. At the end of the last trading period, Squarespace closed at $64.10.
  • Morgan Stanley initiated coverage on DLocal Ltd DLO with an Overweight rating. The price target for DLocal is set to $72.00. The current stock performance of DLocal shows a 52-week-high of $49.90 and a 52-week-low of $29.57. Moreover, at the end of the last trading period, the closing price was at $47.79.
  • Cantor Fitzgerald initiated coverage on PDS Biotechnology Corp PDSB with an Overweight rating. The price target for PDS Biotechnology is set to $25.00. In the first quarter, PDS Biotechnology showed an EPS of $0.14, compared to $0.39 from the year-ago quarter. The current stock performance of PDS Biotechnology shows a 52-week-high of $13.48 and a 52-week-low of $1.30. Moreover, at the end of the last trading period, the closing price was at $11.00.
  • With a Buy rating, Craig-Hallum initiated coverage on comScore Inc SCOR. The price target seems to have been set at $7.00 for comScore. In the first quarter, comScore showed an EPS of $0.36, compared to $0.12 from the year-ago quarter. The stock has a 52-week-high of $4.99 and a 52-week-low of $1.80. At the end of the last trading period, comScore closed at $4.54.
  • With a Buy rating, Maxim Group initiated coverage on Mind Medicine Inc MNMD. The price target seems to have been set at $6.00 for Mind Medicine. Mind Medicine earned $0.04 in the first quarter. The stock has a 52-week-high of $5.77 and a 52-week-low of $2.85. At the end of the last trading period, Mind Medicine closed at $3.72.
  • For Digitiliti Inc DIGI, HC Wainwright & Co. initiated coverage, by setting the current rating at Neutral. The current stock performance of Digitiliti shows a 52-week-high of $0.05 and a 52-week-low of $0.00. Moreover, at the end of the last trading period, the closing price was at $0.03.
  • Barclays initiated coverage on Squarespace Inc SQSP with a Equal-Weight rating. The price target for Squarespace is set to $70.00. At the moment, the stock has a 52-week-high of $64.71 and a 52-week-low of $42.82. Squarespace closed at $64.10 at the end of the last trading period.
  • With an Outperform rating, Cowen & Co. initiated coverage on Paysafe Ltd PSFE. The price target seems to have been set at $15.00 for Paysafe. In the first quarter, Paysafe earned $0.07. The stock has a 52-week-high of $15.65 and a 52-week-low of $10.08. At the end of the last trading period, Paysafe closed at $12.21.
  • With a Buy rating, Roth Capital initiated coverage on Panbela Therapeutics Inc PBLA. The price target seems to have been set at $10.00 for Panbela Therapeutics. Interestingly, in the first quarter, Panbela Therapeutics's EPS was $0.23. The current stock performance of Panbela Therapeutics shows a 52-week-high of $8.80 and a 52-week-low of $3.17. Moreover, at the end of the last trading period, the closing price was at $3.84.
  • For Albany International Corp AIN, Truist Securities initiated coverage, by setting the current rating at Hold. In the first quarter, Albany Intl showed an EPS of $0.87, compared to $0.78 from the year-ago quarter. At the moment, the stock has a 52-week-high of $93.43 and a 52-week-low of $46.31. Albany Intl closed at $92.25 at the end of the last trading period.
  • Truist Securities initiated coverage on Paya Holdings Inc PAYA with a Buy rating. The price target for Paya Holdings is set to $15.00. Interestingly, in the first quarter, Paya Holdings's EPS was $0.07. At the moment, the stock has a 52-week-high of $15.00 and a 52-week-low of $8.99. Paya Holdings closed at $10.41 at the end of the last trading period.
  • For Salesforce.com Inc CRM, Redburn Partners initiated coverage, by setting the current rating at Buy. For the first quarter, Salesforce.com had an EPS of $1.21, compared to year-ago quarter EPS of $0.70. At the moment, the stock has a 52-week-high of $284.50 and a 52-week-low of $180.00. Salesforce.com closed at $241.87 at the end of the last trading period.
  • With a Buy rating, Needham initiated coverage on Thryv Holdings Inc THRY. The price target seems to have been set at $42.00 for Thryv Holdings. Thryv Holdings earned $1.07 in the first quarter. At the moment, the stock has a 52-week-high of $36.92 and a 52-week-low of $8.10. Thryv Holdings closed at $35.07 at the end of the last trading period.
  • With a Neutral rating, Goldman Sachs initiated coverage on DLocal Ltd DLO. The price target seems to have been set at $30.00 for DLocal. The current stock performance of DLocal shows a 52-week-high of $49.90 and a 52-week-low of $29.57. Moreover, at the end of the last trading period, the closing price was at $47.79.
  • Guggenheim initiated coverage on Repare Therapeutics Inc RPTX with a Buy rating. The price target for Repare Therapeutics is set to $46.00. Repare Therapeutics earned $0.58 in the first quarter. The current stock performance of Repare Therapeutics shows a 52-week-high of $46.44 and a 52-week-low of $21.45. Moreover, at the end of the last trading period, the closing price was at $33.50.

See all analyst ratings initiations.

Posted In: BZI-RatingsUpgradesDowngradesInitiationIntraday UpdateAnalyst Ratings

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.